AlloVir rises on positive data for lead cell therapy

Kalaris Therapeutics

26/04/2023 13:56

** Shares of cell therapy developer AlloVir Inc  ALVR.O 
rise 2.34% to $3.56 premarket
    ** Co announces positive results including mortality data of
its lead cell therapy posoleucel in those who have received cell
transplant therapy 
    ** Posoleucel is an investigational multi-virus specific T
cell therapy in mid-stage study
    ** Day 400 non-relapse mortality was 0% - ALVR
    ** Late-stage trials continue to progress with patient
enrollment in U.S., Europe and Asia with data readouts on track
for 2024
    ** Stock down ~32% YTD, as of last close

 (Reporting by Sriparna Roy)
 ((Sriparna.Roy@thomsonreuters.com;))